Skip to main content
SpringerLink
Log in

Recombinant Antibody Fusion Proteins for Cancer Immunotherapy

  • Chapter
Attempts to Understand Metastasis Formation III

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 213/3))

Abstract

The last decade has seen the extensive development of monoclonal antibodies (mAb) combined with rapid advances in recombinant DNA technologies. These developments have greatly accelerated and expanded research efforts to generate new approaches for cancer therapy. The focus of many such efforts has been on immunotherapy, because of the unique specificity, diversity, and biological activity of antibodies that make them potentially ideal reagents in the laboratory and the clinic. Initial emphasis was primarily placed on mAb directed against tumor-associated antigen, including growth factor receptors, expressed to a greater extent on the cell surface of tumor cells than on normal cells and tissues. Two basic strategies were applied to substantially reduce tumor cell dissemination and growth in preclinical models as well as in clinical applications. The first of these made use of antitumor antibodies simply as vehicles to deliver to tumor cells either radionuclides, chemotherapeutic drugs, or toxins conjugated to these mAb by various means. Although several of these approaches resulted in some modest successes in the clinic, these were mainly confined to mAb conjugates with either radionuclides or toxins when applied to certain sensitive tumors, such as non-Hodgkins lymphoma. The second strategy applied to suppress tumor dissemination and growth made use of the natural effector mechanisms of antibodies to destroy tumor cells. These include triggering the complement cascade at the tumor cell surface, with consequent lysis or binding to Fc receptors on the surface of specialized effector cells, such as phagocytes or natural killer (NK) cells, thereby triggering phagocytosis or antibody-dependent cell-mediated cytolysis (ADCC).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ashkenazi A, Capon Dl, Ward RHR (1993) Immunoadhesins. Int Rev Immunol 10: 219–227

    Article  PubMed  CAS  Google Scholar 

  • Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA (1991) Effect of a chimeric antiganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51: 144–149

    PubMed  CAS  Google Scholar 

  • Brinkmann U, Pastan I (1994) Immunotoxins against cancer. Biochim Biophys Acta 1198: 27–45

    PubMed  CAS  Google Scholar 

  • Bruchelt G, Handgretinger R, Kimmig A, Goeke B, Siedner R, Reisfeld RA, Niethammer D, Treuner J (1989) Effects of granulocytes on human neuroblastoma cells measured by chemiluminescence and chromium-51 release assay. J Biolumin Chemolumin 3: 93–103

    Article  CAS  Google Scholar 

  • Burke F, Naylor NS, Davies B, Balkwill F (1993) The cytokine wall chart. Immunol Today 14: 165–170

    Article  PubMed  CAS  Google Scholar 

  • Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd S, Pantoliano MW, Milenic DE, Schlom J (1990) in vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82: 1191–1197

    Article  PubMed  CAS  Google Scholar 

  • Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48–51

    Article  PubMed  CAS  Google Scholar 

  • Dohlsten M, Abrahmsen L, Bjork P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NRJ, Forberg C, Lind P, Kalland T (1994) Monoclonal antibody super antigen fusion proteins: tumorspecific agents for T cell based tumor therapy. Proc Natl Acad Sci USA 91: 8945–8949

    Article  PubMed  CAS  Google Scholar 

  • Dorai H, McCartney JE, Hudziak RM, Tai M-S, Laminet AA, Houston LL, Huston JS, Oppermann H (1994) Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains. Biotechnology 12: 890–897

    Article  PubMed  CAS  Google Scholar 

  • Favort MC, Floret D, Negrier S, Cochat P, Bouffet E, Dacheng Z, Franks CR, Bijman T, Brunat-Mentigny M, Philip I, Philip T (1989) Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 4: 499–504

    Google Scholar 

  • Fell HP, Gayle MA, Grossmaire L, Ledbetter JA (1991) Genetic construction and characterization of a fusion protein consisting of a chimeric F (ab’) with specificity for carcinomas and human IL2. J Immunol 146: 2446–2452

    PubMed  CAS  Google Scholar 

  • Feng GS, Gray PW, Shepard HM, Taylor MW (1988) Antiproliferative activity of a hybrid protein between interferon-y and tumor necrosis factor-ß. Science 241: 1501–1503

    Article  PubMed  CAS  Google Scholar 

  • Gillies SD, Wesolowski JS (1990) Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Hum Antibody Hybridomas 1: 47–54

    CAS  Google Scholar 

  • Gillies SD, Lo K-M, Wesolowski JS (1989) High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 125: 191–202

    Article  PubMed  CAS  Google Scholar 

  • Gillies SD, Wesolowski JS, Lo K-M (1991a) Targeting human cytotoxic T lymphocytes to kill heterologous epidermal growth factor receptor-bearing cells. J Immunol 146: 1067–1071

    PubMed  CAS  Google Scholar 

  • Gillies SD, Young D, Lo K-M, Foley SF, Reisfeld RA (1991b) Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 3: 347–356

    Article  Google Scholar 

  • Gillies SD, Reilly EB, Lo K-M, Reisfeld RA (1992) Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89: 1428–1432

    Article  PubMed  CAS  Google Scholar 

  • Gillies SD, Young D, Lo K-M, Roberts S (1993) Biological activity and in vivo clearance of anti-tumor antibody/cytokine fusion proteins. Bioconjugate Chem 4: 230–235

    Article  CAS  Google Scholar 

  • Goeddel DV, Aggarwal DD, Gray PW, Leung DSN, Nedwin GE, Palladino MA, Patton JS, Pennica D, Shepard HM, Sugarman BJ, Wong GH (1986) Tumor necrosis factors: gene structure and biological activities. Cold Spring Harbor Symp Quant Biol 51: 597–609

    PubMed  CAS  Google Scholar 

  • Grell M, Zimmermann G, Hülser D, Pfizenmayer K, Schewrich P (1994) TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J Immunol 153: 1963–1972

    PubMed  CAS  Google Scholar 

  • Handgretinger R, Baader P, Dopfer R, Klingbiel T, Reuland P, Reisfeld RA, Treuner J, Niethammer D (1992) A phase I study of neuroblastoma with the anti-ganglioside GD2 study of neuroblastoma with the anti-ganglioside GD2 antibody 14. G2a. Cancer Immunol Immunother 35: 199–204

    Article  PubMed  CAS  Google Scholar 

  • Handgretinger R, Anderson K, Lang P, Dopfer R, Klingbiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Niethammer D (1995) A phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A: 261–267

    Article  PubMed  CAS  Google Scholar 

  • Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM (1990) Augmentation of antibody-dependent cell mediated cytotoxicity following in vivo therapy with interleukin 2. Cancer Res 50: 5234–5239

    PubMed  CAS  Google Scholar 

  • Hank JA, Surfus J, Gan F, Chew T-L, Hong R, Tans K, Reisfeld RA, Seeger RC, Reynolds CP, Bauer M, Wiersma S, Hammond D, Sondel PM (1994) Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 15: 29–37

    Article  CAS  Google Scholar 

  • Havöll EA, Fiers W, North JR (1988) The anti-tumor function of tumor necrosis factor (TNF). J Exp Med 167: 1067–1085

    Article  Google Scholar 

  • Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Goeddel DV, Vandlen RL (1992) Identification of heregulin, a specific activator of p185erb2. Science 256: 1205–1210

    Article  PubMed  CAS  Google Scholar 

  • Hoogenboom HR, Raus JC, Volckaert G (1991) Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule. Biochim Biophys Acta 1096: 345–354

    PubMed  CAS  Google Scholar 

  • Jung G, Honsik CJ, Reisfeld RA, Muller-Eberhard HJ (1986) Activaton of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates. Proc Natl Acad Sci USA 83: 4479–4483

    Article  PubMed  CAS  Google Scholar 

  • Lewis M, Tarhaglia GA, Lee A, Bennett GL, Rice GC, Wang GHW, Chen EY, Goeddel DV (1991) cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species-specific. Proc Natl Acad Sci USA 88: 2830–2834

    Article  PubMed  CAS  Google Scholar 

  • Liu MA, Kranz DM, Kurnick JT, Boyle LA, Levy R, Eisen HN (1985) Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 8648–8652

    Article  PubMed  CAS  Google Scholar 

  • Liu MA, Nussbaum SR, Eisen HN (1988) Hormone conjugated with antibody to CD3 mediates cytotoxic T-cell lysis of human melanoma cells. Science 239: 395–398

    Article  PubMed  CAS  Google Scholar 

  • Loetscher H, Pan YC, Lahn HW, Gentz R, Kufe DW (1990) Molecular cloning and expression of the human 55 kDa tumor necrosis factor receptor. Cell 61: 351–359

    Article  PubMed  CAS  Google Scholar 

  • Moonen P, Mermod J-J, Ernst JF, Herschi M, DeLemarter JF (1987) Increased biological activity of deglycosylated recombinant human granulocyte/macrophage colony-stimulating factor produced by yeast animal cells. Proc Natl Acad Sci USA 84: 4428–4433

    Article  PubMed  CAS  Google Scholar 

  • Mueller BM, Reisfeld RA, Gillies SD (1990) Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA 87: 5702–5705

    Article  PubMed  CAS  Google Scholar 

  • Mujoo K, Cheresh DA, Yang HM, Reisfeld RA (1987) Disialoganglioside GD2 on human neuroblastoma: target antigen for monoclonal antibody mediated cytolysis and suppression of tumor growth. Cancer Res 47: 1098–1104

    PubMed  CAS  Google Scholar 

  • Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA (1989) Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal anti-ganglioside GD2 antibody 14.18. Cancer Res 49: 2857–2861

    PubMed  CAS  Google Scholar 

  • Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, Legha SS, Ater JL, Jaffe N, Itoh K, Ross Ml, Bucana CD, Thompson L, Cheung L, Rosenblum MG (1994) Phase I trial of murine monoclonal antibody 14.G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12: 184–193

    PubMed  CAS  Google Scholar 

  • Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM (1994) Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol Lett 39: 91–99

    Article  Google Scholar 

  • Pai LH, Pastan I (1994) Immunotoxins and recombinant toxins for cancer treatment In: De Vita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 3–19

    Google Scholar 

  • Pardoll DM (1993) Cancer vaccines. Immunol Today 14: 310–316

    Article  PubMed  CAS  Google Scholar 

  • Reisfeld RA (1992) Potential of genetically engineered monoclonal antibodies for cancer therapy. Pigment Cell Res Suppl 2: 109–112

    CAS  Google Scholar 

  • Reisfeld RA, Cheresh DA (1987) Human tumor antigens. In: Dixon FJ (ed) Advances in immunology, vol 40. Academic, New York, pp 323–377.

    Google Scholar 

  • Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken G, Gruber R, Pichlmaier H, Hirche H, Pichelmair R (1994) Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 343: 1172–1183

    Article  Google Scholar 

  • Rosenberg SA (1988) Immunotherapy of cancer using interleukin-2: current status and future prospects. Immunol Today 9: 58–62

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180–199

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–485

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Yanneli JR, Yang JC, Topalian SL, Schwartzentraber DS, Weber JS, Parkinson DR, Seipp CA, Einhorn JD, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86: 1159–1166

    Article  PubMed  CAS  Google Scholar 

  • Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA (1994) A recombinant antibody interleukin-2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 91: 9626–9630

    Article  PubMed  CAS  Google Scholar 

  • Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH, LoBuglio AF (1992) Phase I trial of the murine monoclonal anti-GD2 antibody 14.G2a in metastatic melanoma. Cancer Res 52: 4342–4347

    PubMed  CAS  Google Scholar 

  • Savage P, So A, Spooner RA, Epenetos AA (1993) A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer 67: 304–310

    Article  PubMed  CAS  Google Scholar 

  • Schall TJ, Lewis M, Koller KJ, Rice GC, Wong GH, Goeddel DV (1990) Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61: 361–370

    Article  PubMed  CAS  Google Scholar 

  • Scherer MT, Ignatowicz L, Winslow G, Kappler J, Marrack P (1993) Superantigens: bacterial and viral proteins that manipulate the immune system. Annu Rev Cell Biol 9: 101–128

    Article  PubMed  CAS  Google Scholar 

  • Schlom J (1995) Monoclonal antibodies in cancer therapy. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer, 2nd edn. Lippincott, Philadelphia, pp 507–521

    Google Scholar 

  • Schlom J, Milenic DE, Roselli M, Colcher D, Bird R, Johnson S, Hardman KD, Guadagui F, Greiner JW (1991) New concepts in monoclonal antibody based radioimmuno-diagnosis and radioimmunotherapy of carcinoma. Nucl Med Biol 18: 425–435

    CAS  Google Scholar 

  • Smith RIF, Morrison SL (1994) Recombinant polymeric IgG: an approach to engineering more potent antibodies. Biotechnology 12: 683–688

    Article  PubMed  CAS  Google Scholar 

  • Takahashi H, Nakada T, Puisieus I (1993) Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259: 1460–1463

    Article  PubMed  CAS  Google Scholar 

  • Tao M-H, Levy R (1993) Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362: 755–758

    Article  PubMed  CAS  Google Scholar 

  • Tepper Rl, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503–510

    Article  PubMed  CAS  Google Scholar 

  • Weil-Hillman G, Schell K, Segal DM, Hank JA, Sosman JA, Sondel PM (1991) Activation of human T cells obtained pre and post-interleukin-2 (IL2) therapy by anti-CD3 monoclonal antibody plus IL2: implications for combined in vivo treatment. J Immunother 10: 267–277

    Article  PubMed  CAS  Google Scholar 

  • Winter G, Milstein C (1991) Man-made antibodies. Nature 349: 293–299

    Article  PubMed  CAS  Google Scholar 

  • Wright A, Shin S-U, Morrison SL (1992) Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 12: 125–168

    PubMed  CAS  Google Scholar 

  • Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402–3408

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scripps Research Institute, 10666 N. Torrey Pines Rd, 92037, La Jolla, CA, USA

    R. A. Reisfeld

  2. Fuji Immuno Pharmaceuticals Corporation, 125 Hartwell Avenue, 02173, Lexington, MA, USA

    S. D. Gillies

Authors
  1. R. A. Reisfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. D. Gillies
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Basel Institute for Immunology, Grenzacherstraße 487, CH-4005, Basel, Switzerland

    Ursula Günthert Ph.D., P.D.

  2. Virchow Klinikum, Chirurgische Abteilung, Robert-Rössle-Klinik, Max-Delbrück-Centrum Berlin, Lindenberger Weg 80, D-13122, Berlin, Germany

    Peter M. Schlag M.D.

  3. Max-Delbrück-Centrum für Molekulare Medizin, Robert-Rössle-Straße 10, D-13122, Berlin, Germany

    Walter Birchmeier Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Reisfeld, R.A., Gillies, S.D. (1996). Recombinant Antibody Fusion Proteins for Cancer Immunotherapy. In: Günthert, U., Schlag, P.M., Birchmeier, W. (eds) Attempts to Understand Metastasis Formation III. Current Topics in Microbiology and Immunology, vol 213/3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80071-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80071-9_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-80073-3

  • Online ISBN: 978-3-642-80071-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation